Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-monthly subcutaneous Mircera for maintenance of hemoglobin in non-dialysis chronic kidney disease anemia
2007-001720-13Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Epoetin alfa RB in anemia of chronic kidney disease, sponsored by Roche. Primary endpoints: Maintenance of hemoglobin during the efficacy evaluation period and Hemoglobin within target range. Started Jun 2007; status: terminated.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2007-001720-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001720-13.